Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems.
. Here’s a closer look.Leqembi, from Japanese drugmaker Eisai, in early January. It's for patients with mild or early cases of dementia tied to Alzheimer’s disease.
Eisai spokeswoman Libby Holman said prescriptions for the drug have been written, and they expect patients to start receiving it “very soon.”A year’s treatment will run about $26,500. Patients who can afford that without insurance will be able to start the treatment if they are deemed a candidate for Leqembi and they find a doctor and health care system prepared to help them.
Health insurers, which run Medicare Advantage coverage, have been sticking to that decision, said a spokesman for the trade group America's Health Insurance Plans. Then the doctor has to decide what caused the condition. It could stem from Alzheimer’s, Parkinson’s disease, a stroke or a brain injury. This planning might include training nurses on how to give the drug and making sure prescribing doctors know how to recognize candidates for it. Care providers also need a plan for how patients will be monitored once they start taking it.Doctors may want to know that such a plan is in place before they feel comfortable writing a prescription, Kremen noted.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Why a new Alzheimer’s drug is having a slow U.S. debutThe first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer's is on sale, but treatment for most patients is still several months away. Here's why.
Lire la suite »
Why a new Alzheimer's drug is having a slow US debutThe first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems.
Lire la suite »
New Alzheimer's drug shows some promise, but has big price tagHow to alleviate ravages of the disease without bankrupting individuals or Medicare program?
Lire la suite »
Caring for Someone With Alzheimer's DiseaseLearn to spot early signs and symptoms of Alzheimer's disease and find out what to expect from the different stages of Alzheimer's.
Lire la suite »